Ensoli Barbara, Fiorelli Valeria, Ensoli Fabrizio, Lazzarin Adriano, Visintini Raffaele, Narciso Pasquale, Di Carlo Aldo, Monini Paolo, Magnani Mauro, Garaci Enrico
National AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
AIDS. 2008 Oct 18;22(16):2207-9. doi: 10.1097/QAD.0b013e32831392d4.
The native HIV-1 Tat protein was chosen as a vaccine candidate based on its key role in the virus life cycle and on the correlation of Tat-specific immune responses with the asymptomatic stage and lower disease progression rates, but also due to its sequence conservation amongst the various HIV clades as well as the adjuvant effects on dendritic cells. Safety, immunogenicity and efficacy data in monkeys support the development of this vaccine concept.
天然HIV-1反式激活因子蛋白被选为疫苗候选物，这是基于其在病毒生命周期中的关键作用、Tat特异性免疫反应与无症状期及较低疾病进展率之间的相关性，还因为它在各种HIV进化枝中的序列保守性以及对树突状细胞的佐剂效应。猴子的安全性、免疫原性和有效性数据支持了这一疫苗概念的研发。
